Dementia Research Today is a free monthly online journal that collates and summarizes the latest research about Dementia, including details on symptoms, alzheimers, senile dementia, causes.

Volume 2 (2005), Issue 1 (January)

1. Pick bodies in a family with presenilin-1 Alzheimer's disease.
   Ann Neurol, 57(1): 139-43. [Abstract] [Full-text]
2. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia.
   Ann Neurol, 57(1): 82-91. [Abstract] [Full-text]
3. AD lesions and infarcts in demented and non-demented Japanese-American men.
   Ann Neurol, 57(1): 98-103. [Abstract] [Full-text]
4. The neuropathogenesis of AIDS.
   Nat Rev Immunol, 5(1): 69-81. [Abstract] [Full-text]
5. Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing.
   Exp Neurol, 191: S95-S103. [Abstract] [Full-text]
6. Standardization and norms for a Hebrew naming test.
   Brain Lang, 92(2): 204-11. [Abstract] [Full-text]
7. Arithmetic word-problem-solving in Huntington's disease.
   Brain Cogn, 57(1): 1-3. [Abstract] [Full-text]
8. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia.
   Am J Epidemiol, 161(2): 114-20. [Abstract] [Full-text]
9. Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains.
   Cereb Cortex, 15(2): 211-20. [Abstract] [Full-text]
10. Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease.
    J Neurosci, 25(1): 157-63. [Abstract] [Full-text]
11. Treatable comorbid conditions and use of VA health care services among patients with dementia.
    Psychiatr Serv, 56(1): 70-5. [Abstract] [Full-text]
12. The allele interaction between apolipoprotein epsilon2 and epsilon4 in Taiwanese Alzheimer's disease patients.
    Acta Psychiatr Scand, 111(1): 38-43. [Abstract] [Full-text]
13. The population distribution of the Met allele at the PRNP129 polymorphism (a high risk factor for Creutzfeldt-Jakob disease) in various regions of France and in West Europe.
    Infect Genet Evol, 5(2): 141-4. [Abstract] [Full-text]
14. A Heidenhain variant of Creutzfeldt-Jakob disease: forensic implication.
    Forensic Sci Int, 146: S51-4. [Abstract] [Full-text]
15. Indicators of neuroprotection with galantamine.
    Brain Res Bull, 64(6): 519-24. [Abstract] [Full-text]
16. Alzheimer disease and Down syndrome: factors in pathogenesis.
    Neurobiol Aging, 26(3): 383-9. [Abstract] [Full-text]
17. Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases.
    Neurobiol Aging, 26(3): 373-82. [Abstract] [Full-text]
18. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease.
    Neurobiol Aging, 26(3): 355-61. [Abstract] [Full-text]
19. Glia and their cytokines in progression of neurodegeneration.
    Neurobiol Aging, 26(3): 349-54. [Abstract] [Full-text]
20. Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study.
    Neurobiol Aging, 26(3): 341-7. [Abstract] [Full-text]
21. The epidemiologic study of dementia: a life-long quest?
    Neurobiol Aging, 26(3): 335-40. [Abstract] [Full-text]
22. Developmental and vascular risk factors for Alzheimer's disease.
    Neurobiol Aging, 26(3): 325-34. [Abstract] [Full-text]
23. Developmental origins of aging in brain and blood vessels: an overview.
    Neurobiol Aging, 26(3): 281-91. [Abstract] [Full-text]
24. Absence of cholinergic deficits in "pure" vascular dementia.
    Neurology, 64(1): 132-3. [Abstract] [Full-text]
25. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease.
    Neurology, 64(1): 129-31. [Abstract] [Full-text]
26. Cerebral glucose metabolism in patients with AD and different APOE genotypes.
    Neurology, 64(1): 102-7. [Abstract] [Full-text]
27. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD.
    Neurology, 64(1): 94-101. [Abstract] [Full-text]
28. Blood pressure levels before dementia.
    Arch Neurol, 62(1): 112-6. [Abstract] [Full-text]
29. Bone mineral density and the risk of Alzheimer disease.
    Arch Neurol, 62(1): 107-11. [Abstract] [Full-text]
30. A 32-year prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study.
    Arch Neurol, 62(1): 55-60. [Abstract] [Full-text]
31. Characterization of the Alzheimer's disease-associated CLAC protein and identification of an amyloid beta-peptide-binding site.
    J Biol Chem, 280(2): 1007-15. [Abstract] [Full-text]
32. Increased cerebrospinal fluid levels of 3,3',5'-triiodothyronine in patients with Alzheimer's disease.
    J Clin Endocrinol Metab, 90(1): 198-202. [Abstract] [Full-text]
33. Candidate gene association study of solute carrier family 11a members 1 (SLC11A1) and 2 (SLC11A2) genes in Alzheimer's disease.
    Neurosci Lett, 374(2): 124-8. [Abstract] [Full-text]
34. Modulation of age at onset of Huntington disease patients by variations in TP53 and human caspase activated DNase (hCAD) genes.
    Neurosci Lett, 374(2): 81-6. [Abstract] [Full-text]
35. Changes in extracellular space size and geometry in APP23 transgenic mice: a model of Alzheimer's disease.
    Proc Natl Acad Sci U S A, 102(2): 479-84. [Abstract] [Full-text]
36. F2-isoprostanes in Alzheimer and other neurodegenerative diseases.
    Antioxid Redox Signal, 7(1): 269-75. [Abstract] [Full-text]
37. Minocycline in phenotypic models of Huntington's disease.
    Neurobiol Dis, 18(1): 206-17. [Abstract] [Full-text]
38. The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components.
    Neurobiol Dis, 18(1): 176-83. [Abstract] [Full-text]
39. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice.
    Neurobiol Dis, 18(1): 134-42. [Abstract] [Full-text]
40. ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease.
    Neurobiol Dis, 18(1): 119-25. [Abstract] [Full-text]
41. Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice.
    Neurobiol Dis, 18(1): 89-99. [Abstract] [Full-text]
42. ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.
    Neurobiol Dis, 18(1): 75-82. [Abstract] [Full-text]
43. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span.
    Neurobiol Dis, 18(1): 32-9. [Abstract] [Full-text]
44. Structure and function of amyloid in Alzheimer's disease.
    Prog Neurobiol, 74(6): 323-49. [Abstract] [Full-text]
45. Cholinergic nicotinic receptor involvement in movement disorders associated with Lewy body diseases. An autoradiography study using [(125)I]alpha-conotoxinMII in the striatum and thalamus.
    Exp Neurol, 191(2): 292-300. [Abstract] [Full-text]
46. Time course and sequence of pathological changes in the cerebellum of microsphere-embolized rats.
    Exp Neurol, 191(2): 266-75. [Abstract] [Full-text]
47. Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain.
    Brain Res, 1031(2): 222-8. [Abstract] [Full-text]
48. Memory evaluation with a new cued recall test in patients with mild cognitive impairment and Alzheimer's disease.
    J Neurol, 252(1): 47-55. [Abstract] [Full-text]
49. Posterior cortical atrophy: variant of Alzheimer's disease? A case series with PET findings.
    J Neurol, 252(1): 27-35. [Abstract] [Full-text]
50. Diagnostic value of the Rotterdam-CAMCOG in post-stroke dementia.
    J Neurol Neurosurg Psychiatry, 76(2): 263-5. [Abstract] [Full-text]
51. The cerebral correlates of different types of perseveration in the Wisconsin Card Sorting Test.
    J Neurol Neurosurg Psychiatry, 76(2): 169-75. [Abstract] [Full-text]
52. Mapping the onset and progression of atrophy in familial frontotemporal lobar degeneration.
    J Neurol Neurosurg Psychiatry, 76(2): 162-8. [Abstract] [Full-text]
53. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
    Bioorg Med Chem, 13(3): 773-83. [Abstract] [Full-text]
54. White matter lesions are associated with cortical atrophy more than entorhinal and hippocampal atrophy.
    Neurobiol Aging, 26(4): 553-9. [Abstract] [Full-text]
55. Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients.
    Neurobiol Aging, 26(4): 455-64. [Abstract] [Full-text]
56. A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease.
    Neurobiol Aging, 26(4): 449-53. [Abstract] [Full-text]
57. Complete ascertainment of dementia in the Swedish Twin Registry: the HARMONY study.
    Neurobiol Aging, 26(4): 439-47. [Abstract] [Full-text]
58. Oxidative stress related markers in the "VITA" and the centenarian projects.
    Neurobiol Aging, 26(4): 429-38. [Abstract] [Full-text]
59. HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses.
    Neurobiol Aging, 26(4): 393-407. [Abstract] [Full-text]
60. Does the AD7c-NTP locus encode a protein?
    Biochim Biophys Acta, 1727(1): 1-4. [Abstract] [Full-text]
61. Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene.
    Hum Mol Genet, 14(3): 447-60. [Abstract] [Full-text]
62. Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer's disease.
    J Biol Chem, 280(3): 1790-6. [Abstract] [Full-text]
63. Age-dependent biphasic changes in ischemic sensitivity in the striatum of Huntington's disease R6/2 transgenic mice.
    J Neurophysiol, 93(2): 758-65. [Abstract] [Full-text]
64. Stimulation of G-proteins in human control and Alzheimer's disease brain by FAD mutants of APP(714-723): implication of oxidative mechanisms.
    J Neurosci Res, 79(3): 368-74. [Abstract] [Full-text]
65. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin.
    J Neural Transm, 112(2): 269-82. [Abstract] [Full-text]
66. Learning facts from fiction: effects of healthy aging and early-stage dementia of the Alzheimer type.
    Neuropsychology, 19(1): 115-29. [Abstract] [Full-text]
67. The role of color in the implicit memory performance of healthy older adults and individuals with Alzheimer's disease.
    Neuropsychology, 19(1): 44-53. [Abstract] [Full-text]
68. Effects of graded levels of physical similarity and density on visual selective attention in patients with Alzheimer's disease.
    Neuropsychology, 19(1): 5-17. [Abstract] [Full-text]
69. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo.
    Proc Natl Acad Sci U S A, 102(3): 892-7. [Abstract] [Full-text]
70. Alternative splicing in the N-terminus of Alzheimer's presenilin 1.
    Neurogenetics, 5(4): 223-7. [Abstract] [Full-text]
71. Comprehensive association analysis of APOE regulatory region polymorphisms in Alzheimer disease.
    Neurogenetics, 5(4): 201-8. [Abstract] [Full-text]
72. Role of the APP promoter in Alzheimer's disease: cell type-specific expression of the beta-amyloid precursor protein.
    Ann N Y Acad Sci, 1030: 310-6. [Abstract] [Full-text]
73. Protective effects of insulin-like growth factor-I on the somatostatinergic system in the temporal cortex of beta-amyloid-treated rats.
    J Neurochem, 92(3): 607-15. [Abstract] [Full-text]
74. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases.
    Eur J Pharm Biopharm, 59(2): 263-72. [Abstract] [Full-text]
75. Application of graph theory: prediction of glycogen synthase kinase-3 beta inhibitory activity of thiadiazolidinones as potential drugs for the treatment of Alzheimer's disease.
    Eur J Pharm Sci, 24(2): 213-8. [Abstract] [Full-text]
76. Metalloproteinase ADAMTS-1 but not ADAMTS-5 is manifold overexpressed in neurodegenerative disorders as Down syndrome, Alzheimer's and Pick's disease.
    Brain Res Mol Brain Res, 133(1): 1-5. [Abstract] [Full-text]
77. Resting SPECT-neuropsychology correlation in very mild Alzheimer's disease.
    Clin Neurophysiol, 116(2): 364-75. [Abstract] [Full-text]
78. Aluminium in Alzheimer's disease: are we still at a crossroad?
    Cell Mol Life Sci, 62(2): 143-58. [Abstract] [Full-text]
79. Evaluation of cholinergic markers in Alzheimer's disease and in a model of cholinergic deficit.
    Neurosci Lett, 375(1): 37-41. [Abstract] [Full-text]
80. Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran.
    Neurosci Lett, 375(1): 1-6. [Abstract] [Full-text]
81. Menatetrenone and vitamin D2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer's disease.
    Bone, 36(1): 61-8. [Abstract] [Full-text]
82. Presenilin 2 familial Alzheimer's disease mutations result in partial loss of function and dramatic changes in Abeta 42/40 ratios.
    J Neurochem, 92(2): 294-301. [Abstract] [Full-text]
83. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment.
    J Neurochem, 92(2): 255-63. [Abstract] [Full-text]
84. Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme.
    J Neurochem, 92(2): 226-34. [Abstract] [Full-text]
85. Involvement of medullary regions controlling sympathetic output in Lewy body disease.
    Brain, 128: 338-44. [Abstract] [Full-text]
86. HIV-1 tat protein induces a migratory phenotype in human fetal microglia by a CCL2 (MCP-1)-dependent mechanism: possible role in NeuroAIDS.
    Glia, 49(4): 501-10. [Abstract] [Full-text]
87. The effects of very early Alzheimer's disease on the characteristics of writing by a renowned author.
    Brain, 128: 250-60. [Abstract] [Full-text]
88. Evidence for a disorder of locomotor timing in Huntington's disease.
    Mov Disord, 20(1): 51-7. [Abstract] [Full-text]
89. Proneness to psychological distress and risk of Alzheimer disease in a biracial community.
    Neurology, 64(2): 380-2. [Abstract] [Full-text]
90. Midlife cardiovascular risk factors and risk of dementia in late life.
    Neurology, 64(2): 277-81. [Abstract] [Full-text]
91. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease.
    Neurology, 64(2): 224-9. [Abstract] [Full-text]
92. Early sympathetic hyperactivity in Huntington's disease.
    Eur J Neurol, 11(12): 842-8. [Abstract] [Full-text]
93. EEG findings in dementia with Lewy bodies causing diagnostic confusion with sporadic Creutzfeldt-Jakob disease.
    Eur J Neurol, 11(12): 838-41. [Abstract] [Full-text]
94. Prediction of on-road driving performance in patients with early Alzheimer's disease.
    J Am Geriatr Soc, 53(1): 94-8. [Abstract] [Full-text]
95. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.
    J Am Geriatr Soc, 53(1): 83-7. [Abstract] [Full-text]
96. Behavioral and mood effects of snoezelen integrated into 24-hour dementia care.
    J Am Geriatr Soc, 53(1): 24-33. [Abstract] [Full-text]
97. Creatine supplementation lowers brain glutamate levels in Huntington's disease.
    J Neurol, 252(1): 36-41. [Abstract] [Full-text]
98. Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo.
    FEBS Lett, 579(3): 753-6. [Abstract] [Full-text]
99. Widespread gamma-secretase activity in the cell, but do we need it at the mitochondria?
    Biochem Biophys Res Commun, 328(1): 1-5. [Abstract] [Full-text]
100. Neural correlates of semantic and behavioural deficits in frontotemporal dementia.
     Neuroimage, 24(4): 1042-51. [Abstract] [Full-text]
101. Amyloid-beta deposition in the cerebral cortex in Dementia with Lewy bodies is accompanied by a relative increase in AbetaPP mRNA isoforms containing the Kunitz protease inhibitor.
     Neurochem Int, 46(3): 253-60. [Abstract] [Full-text]
102. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.
     Biochem Pharmacol, 69(4): 689-98. [Abstract] [Full-text]
103. Vanishing white matter disease in a child presenting with ataxia.
     J Paediatr Child Health, 41(1): 65-7. [Abstract] [Full-text]
104. Dementia: involving patients in storytelling--a caring intervention. A pilot study.
     J Clin Nurs, 14(2): 256-63. [Abstract] [Full-text]
105. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease.
     Proc Natl Acad Sci U S A, 102(4): 1211-6. [Abstract] [Full-text]
106. Ginger extract inhibits beta-amyloid peptide-induced cytokine and chemokine expression in cultured THP-1 monocytes.
     J Altern Complement Med, 10(6): 1009-13. [Abstract] [Full-text]
107. A national study of the location of death for older persons with dementia.
     J Am Geriatr Soc, 53(2): 299-305. [Abstract] [Full-text]
108. Underrecognition of cognitive impairment in assisted living facilities.
     J Am Geriatr Soc, 53(2): 295-8. [Abstract] [Full-text]
109. Decreasing use of percutaneous endoscopic gastrostomy tube feeding for veterans with dementia-racial differences remain.
     J Am Geriatr Soc, 53(2): 242-8. [Abstract] [Full-text]
110. The "steroid dementia syndrome": an unrecognized complication of glucocorticoid treatment.
     Ann N Y Acad Sci, 1032: 191-4. [Abstract] [Full-text]
111. Polyglutamine expansion of huntingtin impairs its nuclear export.
     Nat Genet, 37(2): 198-204. [Abstract] [Full-text]
112. Frontotemporal dementia, semantic dementia, and Alzheimer's disease: the contribution of standard neuropsychological tests to differential diagnosis.
     J Geriatr Psychiatry Neurol, 18(1): 39-44. [Abstract] [Full-text]
113. Neuropsychology of vitamin B12 deficiency in elderly dementia patients and control subjects.
     J Geriatr Psychiatry Neurol, 18(1): 33-8. [Abstract] [Full-text]
114. Diffusion tensor imaging of frontal white matter microstructure in early Alzheimer's disease: a preliminary study.
     J Geriatr Psychiatry Neurol, 18(1): 12-9. [Abstract] [Full-text]
115. Screening of dementia in stroke patients with lacunar infarcts: comparison of the mattis dementia rating scale and the mini-mental state examination.
     J Geriatr Psychiatry Neurol, 18(1): 3-7. [Abstract] [Full-text]
116. Vitamin B12, folate, homocysteine and dementia: are they really related?
     Arch Gerontol Geriatr, 40(2): 139-46. [Abstract] [Full-text]
117. Plasma homocysteine levels and cognitive status in long-term stay geriatric patients: a cross-sectional study.
     Arch Gerontol Geriatr, 40(2): 129-38. [Abstract] [Full-text]
118. Methionine oxidation by reactive oxygen species: reaction mechanisms and relevance to Alzheimer's disease.
     Biochim Biophys Acta, 1703(2): 111-9. [Abstract] [Full-text]
119. Fall-related brain injuries and the risk of dementia in elderly people: a population-based study.
     Eur J Neurol, 12(2): 86-92. [Abstract] [Full-text]
120. Paradoxical features of word finding difficulty in primary progressive aphasia.
     Ann Neurol, 57(2): 204-9. [Abstract] [Full-text]
121. Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration.
     Ann Neurol, 57(2): 216-25. [Abstract] [Full-text]
122. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.
     Clin Chem, 51(2): 336-45. [Abstract] [Full-text]
123. Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease.
     FASEB J, 19(2): 255-7. [Abstract] [Full-text]

© 2004-2008 Dementia Research Today. All Rights Reserved.